Clinical Trial Update: MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis [Phase 4]

View source ↗

Summary

Sanofi-sponsored Phase 4 trial evaluating levofloxacin for pulmonary multidrug-resistant tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis Pulmonary

Drugs mentioned

• Levofloxacin (Levofloxacin)

Snippet

Sponsor: Sanofi | Conditions: Tuberculosis, Pulmonary | Phase 4 | Status: COMPLETED